* Leap Therapeutics Inc LPTX.OQ reported a quarterly
adjusted
loss of 15 cents per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 10 cents per share.
* Reported revenue was zero; analysts expected $76.00
thousand.
* Leap Therapeutics Inc's reported EPS for the quarter was a
loss
of 15 cents.
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Leap Therapeutics Inc shares had risen by 13.0% this
quarter and
lost 59.9% so far this year.
* The company reported a quarterly loss of $17.02 million.
* Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $4.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 12
at 12:09 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.10 -0.15 Missed
Mar. 31 2022 -0.10 -0.09 Beat
Dec. 31 2021 -0.11 -0.10 Beat
Sep. 30 2021 -0.11 -0.14 Missed